目的:对加巴喷丁用于原发性三叉神经痛治疗的可行性及安全性进行研究,证实加巴喷丁的临床价值。方法:以我院2011年8月-2012年8月间采用药物治疗的72例原发性三叉神经痛患者为研究对象,采用随机抽签的方法将其分为两组,每组36例。一组研究对象采用口服加巴喷丁进行治疗,为观察组;一组研究对象采用口服卡马西平进行治疗,为对照组。连续治疗2个月后对研究对象的疼痛程度、疗效及不良反应等数据比较及统计学分析。结果:治疗2个月后观察组平均视觉模拟评分为(1.3±0.6)分,对照组平均模拟评分为(1.4±0.5)分,组间比较无显著差异性(P>0.05);观察组研究对象显效18例,有效15例,无效3例,总有效率为91.7%高于对照组83.3%的总有效率,且具有显著差异性(P<0.05);两组研究对象的不良反应发生率分别为8.33%和19.4%,观察组低于对照组,且具有显著差异性(P<0.05)。结论:加巴喷丁用于原发性三叉神经痛的治疗具有疗效显著,不良反应率低等优势,证实加巴喷丁用于原发性三叉神经痛安全可行。 Objective: To study the feasibility and safety of gabapentin in the treatment of primary trigeminal neuralgia, confirming the clinical value of gabapentin. Methods: A total of 72 patients with primary trigeminal neuralgia treated with drugs from August 2011 to August 2012 in our hospital were enrolled in this study. Patients were divided into two groups (n = 36) by random sampling. A group of subjects treated with oral gabapentin for the observation group; a group of subjects treated with oral carbamazepine for the control group. After 2 months of continuous treatment, the data of the pain degree, curative effect and adverse reactions of the study subjects were compared and statistically analyzed. Results: After 2 months of treatment, the mean visual analogue score of the observation group was (1.3 ± 0.6) points, and the average simulated score of the control group was (1.4 ± 0.5) points. There was no significant difference between the two groups (P> 0.05) The effective rate was 91.7%, which was significantly higher than that of the control group (83.3%), with significant difference (P <0.05). The incidence of adverse reactions in the two groups was significantly higher than that in the control group Respectively 8.33% and 19.4%, the observation group is lower than the control group, and has significant difference (P <0.05). Conclusion: Gabapentin has the advantages of significant curative effect and low rate of adverse reactions in the treatment of primary trigeminal neuralgia, confirming that gabapentin is safe and feasible for primary trigeminal neuralgia.